<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Sil&#39;s Science Corner on Medium]]></title>
        <description><![CDATA[Stories by Sil&#39;s Science Corner on Medium]]></description>
        <link>https://medium.com/@silsangkharlukhi?source=rss-0750f75512f6------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*JBD4ORfwyVXKylMNFhW0FA.jpeg</url>
            <title>Stories by Sil&amp;#39;s Science Corner on Medium</title>
            <link>https://medium.com/@silsangkharlukhi?source=rss-0750f75512f6------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 09:07:45 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@silsangkharlukhi/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[From Vape Clouds to Superbugs]]></title>
            <link>https://medium.com/@silsangkharlukhi/from-vape-clouds-to-superbugs-67873bf7f82d?source=rss-0750f75512f6------2</link>
            <guid isPermaLink="false">https://medium.com/p/67873bf7f82d</guid>
            <category><![CDATA[antimicrobial-resistance]]></category>
            <category><![CDATA[copd]]></category>
            <category><![CDATA[e-cigarettes]]></category>
            <category><![CDATA[antibiotic-resistance]]></category>
            <category><![CDATA[microbiology]]></category>
            <dc:creator><![CDATA[Sil's Science Corner]]></dc:creator>
            <pubDate>Sun, 05 Jul 2026 14:20:50 GMT</pubDate>
            <atom:updated>2026-07-05T15:35:41.259Z</atom:updated>
            <content:encoded><![CDATA[<p>E-cigarettes are sold as the safer cousin of the cigarette: no tar, no combustion, just flavoured vapour. But a growing body of evidence suggests vaping isn’t the harmless off-ramp it was marketed as, at least not for your lungs. Follow that thread into the microbiology, and a pattern starts to emerge, one built from four separate lines of evidence that, as far as I can tell, haven’t yet been tested together in a single study: vaping raises the odds of chronic lung disease, and the bacteria that colonise damaged airways respond to e-cigarette exposure by becoming more virulent, more biofilm-forming, and in some communities, more resistant.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*o5JS0A8_ojVFy4A-2o2tEg.jpeg" /><figcaption>Photo by <a href="https://unsplash.com/@cnordic?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">CNordic Nordic</a> on <a href="https://unsplash.com/photos/a-woman-holding-a-video-game-controller-in-her-right-hand-y4iCyVOG5pY?utm_source=unsplash&amp;utm_medium=referral&amp;utm_content=creditCopyText">Unsplash</a></figcaption></figure><p>None of these four pieces alone proves the full chain. But laid out together, they sketch a plausible pathway worth taking seriously, and worth someone testing directly.</p><p>Here’s the case, piece by piece.</p><h3>Step one: the vaping-COPD link is no longer just a hunch</h3><p>A systematic review and meta-analysis pooling 17 studies and over 4.3 million participants found a clear, statistically significant association between e-cigarette use and the odds of having COPD. Current users had roughly 47% greater odds compared to never-vapers, former users 77% greater odds, and ever-users a 39% increase. These held up after adjusting for age, and a leave-one-out sensitivity analysis showed no single study was driving the result.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*-6nwiaue4DDoH9XY-httFw.png" /><figcaption>Odds of COPD by e-cigarette use status, relative to never-users. Adapted from Shabil et al., <em>npj Primary Care Respiratory Medicine</em> (2025).</figcaption></figure><p>The likely mechanism isn’t exotic: e-cigarette aerosols still deliver ultrafine particles, volatile organic compounds and reactive oxygen species into the airway, triggering the same kind of inflammation and remodelling seen in smoking-related COPD. The relative risk looks smaller than for cigarettes, but smaller isn’t the same as safe.</p><h3>Step two: e-cigarette vapour changes bacterial behaviour on contact, not just host tissue</h3><p>A 2019 study in <em>Respiratory Research</em> directly exposed four pathogens central to chronic lung disease (<em>H. influenzae, S. pneumoniae, S. aureus</em> and <em>P. aeruginosa</em>) to e-cigarette vapour extract, cigarette smoke extract, and unexposed controls.</p><p>Bacteria exposed to vapour formed significantly more biofilm, particularly <em>S. aureus</em>, in some cases exceeding the cigarette-smoke effect. When used to infect <em>Galleria mellonella</em> larvae, survival dropped across nearly every species tested. Exposed bacteria also provoked a stronger inflammatory response (higher IL-8 and TNF-alpha) in human airway epithelial cells.</p><p>One nuance worth flagging: the study’s clearest resistance finding, <em>P. aeruginosa</em>’s MIC to tetracycline and doxycycline jumping from 24 and 48 mg/ml to over 256 mg/ml within three days, was produced by cigarette smoke, not e-cigarette vapour. No comparable MIC shift appeared with vapour for any other antibiotic tested. So e-cigarette vapour reliably made these pathogens more persistent and inflammatory, but this study didn’t catch it directly driving resistance the way cigarette smoke did.</p><h3>Step three: bacteria don’t just tolerate the aerosol, they metabolise it into a resistance signal</h3><p>A 2025 paper from University of Michigan researchers looked at what bacterial communities do with e-cigarette aerosol at the metabolite and gene-expression level. Using lab-grown oral biofilms ranging from commensal- to pathogen-dominated, the team found bacteria metabolise both nicotine-containing and nicotine-free aerosol into hundreds of compounds, many functioning as quorum-sensing signals, the chemical language bacteria use to coordinate group behaviour.</p><p>Crucially, the response depended on who was in the community. Pathogen-rich biofilms responded to nicotine-containing aerosol by overexpressing genes linked to antimicrobial resistance, secretion systems, and carbon metabolism. Commensal, health-associated biofilms instead upregulated capsule and cell-wall biosynthesis genes. The same aerosol pushed “good” and “bad” communities in different directions, and the pathogen-rich ones moved towards resistance. Several of the same metabolites turned up in the saliva of real e-cigarette users, suggesting this isn’t just a lab artefact.</p><h3>Step four: COPD as the resistome incubator</h3><p>The final piece is what happens once these pathogens have a damaged airway to settle into. A 2026 <em>Thorax</em> state-of-the-art review lays out how tightly chronic lung disease and antimicrobial resistance are entangled. COPD, bronchiectasis and cystic fibrosis all create environments that key opportunistic pathogens are remarkably good at colonising long-term: up to a third of people with COPD may be sputum culture-positive for <em>H. influenzae</em> or <em>M. catarrhalis</em> at any given time.</p><p>Once established, these organisms behave less like a one-off infection and more like a resistance incubator: spontaneous mutation, horizontal gene transfer, selection of pre-existing resistant subpopulations, and migration of resistant lineages all compound within biofilms that shield bacteria from antibiotics and immune clearance. People with COPD and bronchiectasis carry a measurably wider range of resistance genes than healthy people, tracking bacterial load more than antibiotic exposure alone.</p><h3>Connecting the dots</h3><p>Together, these four pieces make a stronger case than a simple juxtaposition of unrelated papers. Vaping raises the odds of COPD. Pathogens exposed to e-cigarette vapour, whether in the airway or the mouth, respond by forming more biofilm, becoming more virulent, and in pathogen-dominated communities, switching on resistance-associated genes. And a COPD airway is exactly the kind of long-term colonisation site where those mechanisms can accumulate over years. This is a plausible, mechanistically grounded pathway from vaping exposure to an expanded reservoir of resistant, opportunistic pathogens.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*s-lzqfCh2t6qaHabO28y-A.png" /><figcaption>Kwok et al, 2026. WHO priority bacterial pathogens associated with chronic lung infections</figcaption></figure><p>That matters because the WHO’s priority pathogen list overlaps almost exactly with the organisms tested here. Carbapenem-resistant <em>P. aeruginosa</em> and MRSA are already recognised drivers of increased mortality in bronchiectasis and COPD. If e-cigarettes are both expanding the pool of people with damaged airways and nudging colonising bacteria towards resistance, that’s a public health angle that’s had very little attention so far.</p><h3>What we still don’t know</h3><p>Being precise about the gaps matters, because overclaiming does more harm than good in a space this new.</p><p>No one has run a longitudinal resistome study comparing vapers, smokers and never-users at the airway level in people with confirmed COPD. The 2019 <em>Respiratory Research</em> study used reference lab strains rather than clinical isolates, tested a single device and e-liquid, and found its clearest MIC shift with cigarette smoke rather than vapour. The 2025 paper from University of Michigan is focused on the oral cavity rather than the lower airway, and used a single flavour-free, moderate-nicotine e-liquid.</p><p>The COPD-vaping meta-analysis itself has three specific weak points worth naming. First, it leaned heavily on self-reported diagnoses, and the spirometry-confirmed subset fell short of statistical significance. Second, age is a collider here: it’s linked to both COPD risk and e-cigarette use, and adjusting for age alone doesn’t fully untangle that relationship without individual-level data. Third, most included studies didn’t cleanly separate never-smokers from former smokers among vapers, and didn’t consistently account for dual use of e-cigarettes and combustible cigarettes, so some of the apparent vaping effect may reflect residual smoking exposure rather than vaping alone.</p><p>So the fair summary: we have solid mechanistic evidence that e-cigarette exposure changes bacterial virulence and, in disease-associated communities, resistance gene expression. We have solid epidemiological evidence that vaping raises COPD risk, albeit with the caveats above. And we have a thorough account of why chronic lung disease is a resistome-friendly environment. What’s missing is the final clinical link: a study sequencing the airway resistome of long-term vapers with COPD against smokers and non-users. Given how fast e-cigarette use has spread among younger, previously non-smoking populations, that’s a study worth doing soon.</p><h3>The takeaway</h3><p>Vaping was pitched as a way to sidestep the worst of cigarette smoking’s damage. The evidence increasingly suggests it doesn’t fully deliver on that promise, either for the lungs directly or for the bacteria that colonise them. Chronic airway damage of any origin appears to be fertile ground for resistant pathogens, and bench science now shows e-cigarette exposure can nudge those pathogens further in that direction. If e-cigarettes are quietly generating a cohort of people with damaged airways and more resistance-primed bacterial communities, the resistome researchers of the next decade have a clear, well-motivated study waiting for them</p><h3>References</h3><p>Beverly, M. L.-S., Chaudhary, P. P., Dabdoub, S. M., Kim, S., Chatzakis, E., Williamson, K., Ganesan, S. M., Yadav, M., Ratley, G., D’Souza, B. N., Myles, I. A., &amp; Kumar, P. S. (2025). Toxic cultures: E-cigarettes and the oral microbial exposome. <em>NPJ Biofilms and Microbiomes</em>, <em>11</em>(1), 66. <a href="https://doi.org/10.1038/s41522-025-00709-7">https://doi.org/10.1038/s41522-025-00709-7</a></p><p>Gilpin, D. F., McGown, K.-A., Gallagher, K., Bengoechea, J., Dumigan, A., Einarsson, G., Elborn, J. S., &amp; Tunney, M. M. (2019). Electronic cigarette vapour increases virulence and inflammatory potential of respiratory pathogens. <em>Respiratory Research</em>, <em>20</em>(1), 267. <a href="https://doi.org/10.1186/s12931-019-1206-8">https://doi.org/10.1186/s12931-019-1206-8</a></p><p>Kwok, W. C., Pates, K., Shah, A., Jackson, L., &amp; Frost, F. (2026). Antimicrobial resistance in chronic lung infection: The road to resistance. <em>Thorax</em>, <em>81</em>(5), 499–507. <a href="https://doi.org/10.1136/thorax-2024-222396">https://doi.org/10.1136/thorax-2024-222396</a></p><p>Shabil, M., Malvi, A., Khatib, M. N., Ganesan, S., Kaur, M., Srivastava, M., Prasad, G. V. S., Rajput, P., Mohan, B., Jena, D., Bushi, G., Sah, S., Satapathy, P., Samal, S. K., &amp; Mawejje, E. (2025). Association of electronic cigarette use and risk of COPD: A systematic review and meta-analysis. <em>Npj Primary Care Respiratory Medicine</em>, <em>35</em>(1). <a href="https://doi.org/10.1038/s41533-025-00438-6">https://doi.org/10.1038/s41533-025-00438-6</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=67873bf7f82d" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Cutting Out the Extra: How CRISPR Could Change Down Syndrome Treatment]]></title>
            <link>https://medium.com/@silsangkharlukhi/cutting-out-the-extra-how-crispr-could-change-down-syndrome-treatment-55b71996eaa6?source=rss-0750f75512f6------2</link>
            <guid isPermaLink="false">https://medium.com/p/55b71996eaa6</guid>
            <category><![CDATA[crispr]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[downs-syndrome]]></category>
            <category><![CDATA[novel]]></category>
            <category><![CDATA[genetics]]></category>
            <dc:creator><![CDATA[Sil's Science Corner]]></dc:creator>
            <pubDate>Fri, 21 Nov 2025 15:40:05 GMT</pubDate>
            <atom:updated>2025-11-21T15:40:05.240Z</atom:updated>
            <content:encoded><![CDATA[<p>The more the merrier, this is a saying that is very common but this rule doesn’t follow everywhere especially when it comes to the number of chromosomes we humans have. Humans have 23 pairs of chromosomes, 22 pairs of autosomes and one pair of sex chromosomes (XX or XY) those chromosomes are labelled in terms of number (1–22) except for the sex chromosomes, which are known as X and Y chromosomes, these chromosomes play a crucial role in the development of humans.­ However, in some cases there can either be an extra chromosome or a missing chromosome which can lead to a genetic disorder. In the scientific world this abnormal number of chromosomes is termed as aneuploidy.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/562/1*3-Z2wJuWDe2PRwnfqGC5dQ.jpeg" /><figcaption>Figure 1 Extra chromosome 21 (Shen, 2023)</figcaption></figure><p>The estimated incidence of Down syndrome is between 1 in 700 live births; it is a genetic condition specifically affecting chromosome 21. Chromosome 21 has a number of genes that are responsible for coding various proteins that are essential for the bodily functions and also for regulating the activity of the immune system, it is also involved in skeletal muscle growth and the development of the foetus during pregnancy. Now, imagine we have an extra copy number of this chromosome — better function, right? Unfortunately, no, this is the case for a person with Down syndrome. This extra chromosome can disturb the functions of chromosome number 21. Since the immune system is affected, they are more susceptible to infections with dysregulation of both the innate and the adaptive immunity.</p><p><strong>“Why not just cut the extra chromosome?”</strong></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/480/1*3u9y6WV7Cyq7uY1_s_04xA.jpeg" /><figcaption>Emmanuelle Charpentier and Jennifer Doudna, Credit: Miguel Riopa/AFP/Getty Images</figcaption></figure><p>This line would have been sci-fi before the development of CRISPR-Cas9 in 2012. CRISPR-Cas9 can be seen as the molecular scissors of the genetic world, developed by Emmanuelle Charpentier and Jennifer Doudna — this gene editing tool uses components from the adaptive immune system of bacteria. In simple terms, CRISPR works like a GPS-guided scissor: a guide RNA locates the target DNA sequence, and the Cas9 enzyme cuts it precisely. Since the development of this technique, many scientists and researchers have modified and developed it to fit the objective of their research. Recently, <a href="https://pubmed.ncbi.nlm.nih.gov/39967679/">a team of researchers from Japan has managed to pave the way for a potential treatment for Down syndrom</a>e.</p><p><strong>“So how did they actually do it? The process was surprisingly elegant.”</strong></p><p>Since individuals with Down syndrome have three copies of chromosome 21 that are nearly identical, the scientists had to ensure they were targeting the extra chromosome without damaging the two copies required for normal functioning.</p><p>Their brilliant approach involved using cells from an individual with Down syndrome to create four different cell lines. One cell line contained all three chromosomes, whilst the other three cell lines each contained only one of the three chromosome 21 copies isolated. By comparing these isolated chromosomes, the researchers could identify the unique DNA “fingerprints” of each one — rather like finding which key on a keyring doesn’t actually belong there. Identifying the extra chromosome was the first crucial hurdle.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*GMx0y2NnVk2SMRI358cLQw.jpeg" /><figcaption>Model figure of CRISPR-Cas9 working (Wilson, 2022)</figcaption></figure><p>They targeted the maternal chromosome and termed it M2, since in most cases (not all) the extra chromosome is derived from the egg during meiosis which is a type of cell division. They then developed a unique guide RNA that helped the Cas9 protein make cuts in their desired DNA region within M2. This unique guide RNA prevented Cas9 protein from making incisions in the other chromosome. It is at this step that the researchers made the grand discovery that one incision is not enough, due to our highly efficient DNA repair mechanism our body would immediately get on with repairing that one incision, therefore the researchers made about 13 incisions, and that increased the success rate from 1% up to 13.1%.</p><p>The researchers used multiple methods to confirm they’d removed the correct chromosome. They employed fluorescent probes that made each chromosome glow under a microscope, genetic fingerprinting to identify which specific chromosome was lost, and even created special cells where each chromosome 21 copy glowed a different color (blue, red, or green). In every successful case, it was the targeted M2 chromosome that disappeared, proving their precision.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*XNZJYTdo7yjo2n3qlIt4lg.png" /><figcaption>(Hashizume et al., 2025)</figcaption></figure><p>To further improve their success rate, the researchers employed a clever trick: they temporarily weakened the cells’ DNA repair systems by blocking two key repair proteins called LIG4 and POLQ. This intervention lasted only 48 hours — just long enough for cells to discard the damaged chromosome before their repair mechanisms kicked back in. This approach nearly doubled their success rate in some experiments.</p><p>They tested this method on two types of cells — stem cells which are actively dividing and regular skin cells which are not dividing. They saw that after applying their technique to both stem cells and regular skin cells the extra chromosome was deleted with a success rate of 13–17% and 13.9%, respectively. This finding is particularly significant since the majority of cells in our body such as the heart and neurons are in a non-dividing state, demonstrating effectiveness in both cell types significantly broadens the potential therapeutic applications.</p><p><strong>“The real question remained: would correcting the chromosome actually improve the cells?”</strong></p><p>Their findings were efficacious. After the removal of the extra chromosome, the cells showed significant improvement. The cells’ gene expression was improved with the overall gene signature being closest to normal, and the genes that are responsible for brain development became more active, their cellular health improved and they divided more effectively compared to the cells with the extra chromosome, and lastly they did not see any significant changes to the chromosome’s structure, there were no missing chromosomes; but there were just slight changes in the area where the incisions were made.</p><p>It’s crucial to understand what this treatment could and couldn’t do. For someone already born with Down syndrome, this approach wouldn’t reverse physical features like facial characteristics or bone structure, those developed during pregnancy and are already established. However, it could potentially improve ongoing health issues like immune function, reduce the risk of early-onset Alzheimer’s disease, and possibly enhance cognitive function going forward.</p><p>If this technology advances to clinical use, it could serve two purposes: prenatal application might prevent Down syndrome from developing entirely (though this raises complex ethical questions), while postnatal treatment could improve quality of life for people already living with the condition.</p><p>This represents just the first stage in finding a treatment for Down syndrome, but it looks promising. Any potential treatment would require extensive clinical trials before being approved for use in humans. It’s important to note that many individuals with Down syndrome and their families lead fulfilling lives, and this research aims to address specific health challenges rather than suggesting Down syndrome needs to be ‘cured.’ Any future treatments would be a choice for families to consider.</p><p><strong>References</strong></p><p>Hashizume, R., Wakita, S., Sawada, H., Shin-ichiro Takebayashi, Yasuji Kitabatake, Miyagawa, Y., … Hiroki Kurahashi. (2025). Trisomic rescue via allele-specific multiple chromosome cleavage using CRISPR-Cas9 in trisomy 21 cells. <em>PNAS Nexus</em>, <em>4</em>(2). <a href="https://pubmed.ncbi.nlm.nih.gov/39967679/">https://doi.org/10.1093/pnasnexus/pgaf022</a></p><p><a href="https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/trisomy-21">Shen, C.-H. (2023). <em>Diagnostic Molecular Biology</em>. Academic Press.</a></p><p>United Nations. (2023). World Down Syndrome Day. Retrieved from United Nations website:<a href="https://www.un.org/en/observances/down-syndrome-day"> https://www.un.org/en/observances/down-syndrome-day</a></p><p>Wilson, R. (2022). CRISPR Technology. Retrieved from Innovative Genomics Institute (IGI) website: <a href="https://innovativegenomics.org/crisprpedia/crispr-technology/">https://innovativegenomics.org/crisprpedia/crispr-technology/</a></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=55b71996eaa6" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Phage Therapy: A New Weapon Against Antibiotic-Resistant Infections in CF]]></title>
            <link>https://medium.com/@silsangkharlukhi/phage-therapy-a-new-weapon-against-antibiotic-resistant-infections-in-cf-87ea002b6fe4?source=rss-0750f75512f6------2</link>
            <guid isPermaLink="false">https://medium.com/p/87ea002b6fe4</guid>
            <category><![CDATA[science]]></category>
            <category><![CDATA[cystic-fibrosis]]></category>
            <category><![CDATA[microbiology]]></category>
            <category><![CDATA[phage-therapy]]></category>
            <category><![CDATA[medicine]]></category>
            <dc:creator><![CDATA[Sil's Science Corner]]></dc:creator>
            <pubDate>Sun, 12 Oct 2025 21:19:23 GMT</pubDate>
            <atom:updated>2025-10-12T21:19:23.575Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*K1u4pNZGkKB8KGzYZ7yCjA.jpeg" /></figure><p>Imagine trying to breathe through a straw whilst someone slowly pours honey into your lungs. Every breath becomes a battle. Every cough, exhausting. This is the daily reality for people living with cystic fibrosis (CF) a genetic condition that causes thick, sticky mucus to build up in the lungs and other organs, making breathing increasingly difficult.</p><p>Whilst CF itself is genetic, the condition creates the perfect environment for bacterial infections to take hold, and these infections often become the real threat to patients’ lives. In my previous blog, I talked about the<a href="https://medium.com/@silsangkharlukhi/why-antibiotics-arent-popcorn-understanding-antimicrobial-resistance-5493a5156951"> ESKAPE pathogens</a>, a group of bacteria that are becoming increasingly resistant to antibiotics. Today, I want to focus on one particular member of this notorious group: <a href="https://www.cdc.gov/pseudomonas-aeruginosa/about/index.html"><em>Pseudomonas aeruginosa</em>.</a></p><h3><strong>The Main Culprit</strong></h3><p><em>P. aeruginosa</em> is the leading bacterial cause of lung infections in CF patients. This opportunistic bacterium takes advantage of the damaged, mucus-filled airways to set up camp in the lungs, where it forms stubborn colonies that are incredibly difficult to shift. For CF patients, these infections trigger what’s called “exacerbations” periods where symptoms dramatically worsen, lung function drops, and hospitalisation becomes necessary.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/700/1*dVCqxjfyPb56J_7OHg-mWw.jpeg" /><figcaption><a href="https://phil.cdc.gov/Details.aspx?pid=23249">Pseudomonas aeruginosa</a> (Centers for Diseases Control and Prevention)</figcaption></figure><p>Here’s what makes <em>P. aeruginosa</em> particularly troublesome: it’s become increasingly resistant to multiple antibiotics. Over recent years, only a handful of new antibiotics have been approved to treat it, and the ones we have are becoming less effective. It’s like trying to fight a battle with a shrinking arsenal of weapons.</p><h3><strong>Enter the Phages</strong></h3><p>But what if instead of trying to poison the bacteria with antibiotics, we could send in a natural enemy? That’s exactly what bacteriophages or “phages” for short do. These are viruses that specifically hunt and kill bacteria whilst leaving human cells completely unharmed. Scientists have known about phages for over a century, but we’re only now beginning to harness their potential properly.</p><p><a href="https://www.nih.gov/news-events/news-releases/nih-supported-clinical-trial-phage-therapy-cystic-fibrosis-begins">The National Institute of Allergy and Infectious Diseases in the United States has launched a clinical trial testing a phage cocktail called WRAIR-PAM-CF1.</a> This experimental treatment contains four different types of phages, each one programmed by nature to target <em>P. aeruginosa</em>. Think of them as precision-guided missiles that only lock onto their bacterial targets.</p><h3><strong>How It Works</strong></h3><p>The trial is enrolling up to 72 adults with CF across 16 centres in America. Participants receive a single intravenous infusion of the phage cocktail at varying doses. The study follows a careful two-phase approach: first testing safety in small groups, then expanding to a larger, double-blinded trial where neither patients nor doctors know who’s receiving the real treatment versus a placebo.</p><p>Researchers are measuring not just whether it’s safe, but whether it actually reduces the bacterial load in patients’ lungs, improves their lung function, and ultimately, enhances their quality of life.</p><h3><strong>Where We Stand</strong></h3><p>The trial has only just begun enrolling patients, so there are no results yet. However, the fact that this research is happening at all represents a significant shift. For decades, phage therapy remained largely theoretical in Western medicine, despite being used in parts of Eastern Europe for years and as someone who worked with bacteriophages in my master’s research, seeing this technology finally reach clinical trials feels like watching science fiction become reality.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*770OiMVWpRH88PjPXSqDUQ.jpeg" /><figcaption>An illustration for clinical trials</figcaption></figure><p>For CF patients who’ve watched their treatment options dwindle as bacteria grow more resistant, this trial offers something precious: hope. It’s not a cure for CF itself, but if successful, phage therapy could provide a powerful new tool to manage the bacterial infections that so often determine these patients’ quality of life and longevity.</p><p>The road ahead is long, but for those struggling to breathe, even a glimmer of light makes the journey worthwhile.</p><h3>Read More</h3><ul><li><a href="https://medium.com/@silsangkharlukhi/why-antibiotics-arent-popcorn-understanding-antimicrobial-resistance-5493a5156951">Why Antibiotics Aren’t Popcorn: Understanding Antimicrobial Resistance</a></li><li><a href="https://www.nih.gov/news-events/news-releases/nih-supported-clinical-trial-phage-therapy-cystic-fibrosis-begins">NIH-Supported Clinical Trials of Phage Therapy For Cystic Fibrosis Begins</a></li></ul><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=87ea002b6fe4" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Why Antibiotics Aren’t Popcorn: Understanding Antimicrobial Resistance]]></title>
            <link>https://medium.com/@silsangkharlukhi/why-antibiotics-arent-popcorn-understanding-antimicrobial-resistance-5493a5156951?source=rss-0750f75512f6------2</link>
            <guid isPermaLink="false">https://medium.com/p/5493a5156951</guid>
            <category><![CDATA[bacteriophages]]></category>
            <category><![CDATA[antibiotics]]></category>
            <category><![CDATA[antibiotic-resistance]]></category>
            <category><![CDATA[research]]></category>
            <category><![CDATA[microbiology]]></category>
            <dc:creator><![CDATA[Sil's Science Corner]]></dc:creator>
            <pubDate>Fri, 10 Oct 2025 14:02:23 GMT</pubDate>
            <atom:updated>2025-10-10T14:02:23.675Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*T-tiB_HLEACJuY0HBv8Nfw.jpeg" /></figure><h3>The Problem We Don’t Talk About Enough</h3><p>A common line I’ve heard when someone was sick back home, where medication was not as regulated as it is in the UK, was “Pop an antibiotic and you’ll be fine.” Not knowing the dangers that follows this.</p><p>I recently completed my master’s and the topic I worked on was something dealing with AMR. AMR? Well, AMR stands for Antimicrobial Resistance. This is basically bacteria, or so-called “germs” that make us sick, that have grown resistance to those antibiotics that we eat like popcorn.</p><h3>How It All Started: A Happy Accident</h3><p>Antibiotics or to be more precise the first antibiotic penicillin was discovered by Alexander Fleming by mistake, and let’s say that mistake has saved many<a href="https://www.ibms.org/resource/penicillin-the-war-time-miracle-drug-that-saved-millions.html"> individuals during WW2</a> and even till date. From that penicillin, many other scientists have been able to formulate different types of antibiotics, and many other types of them have been found.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*4R8rj6yyG9fx5S5M8lDeLQ.jpeg" /><figcaption>Alexander Fleming</figcaption></figure><p>During the initial years when penicillin was found, it was really effective. This was because the bacteria didn’t know how to “fight” this enemy. But due to constant exposure to it, many bacteria have grown resistance to them.</p><h3>Meet the ESKAPE Pathogens</h3><p>A famous group of AMR in the scientific community is the ESKAPE Pathogens. This is a group of six bacteria, namely <em>Enterococcus faecium</em>, <em>Staphylococcus aureus</em>, <em>Klebsiella pneumoniae</em>, <em>Acinetobacter baumannii</em>, <em>Pseudomonas aeruginosa</em>, and <em>Enterobacter</em> spp., that have risen up the podium of AMR.</p><p><a href="https://www.who.int/news/item/17-05-2024-who-updates-list-of-drug-resistant-bacteria-most-threatening-to-human-health">According to the WHO</a>, the worst part is that they have the ability to “escape” the treatment that used to work on them initially but due to constant exposure those antibiotics aren’t as effective now. For this reason, this has forced scientists to find other alternatives to combat bacterial infections.</p><h3>My Research: Using Viruses as Trojan Horses</h3><p>One of the methods is using a virus known as bacteriophage that targets and “eats” bacteria. This is the method that I was working on in my master’s project. I was using this virus as a vehicle, or in scientific work as a vector, to take an antimicrobial property such as zinc to the bacteria to kill it.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/500/1*qmiFHLts3ZcOc3t-Is6h9Q.png" /><figcaption>Common structure of a Bacteriophage</figcaption></figure><p>You must be wondering, why can’t I just use the virus? The main reason is that just like us humans, viruses are also picky and they don’t eat anything. So, finding a virus that will work on each ESKAPE pathogen is like finding a needle in a haystack.</p><p>Since there are papers that show evidence that <a href="https://www.nature.com/articles/s41598-022-06657-y">nanoparticles like zinc have antimicrobial properties</a>, and also these are so tiny that they can be attached to the back of those viruses, as easy as it sounds its actually really hard to achieve but more efficient compared to finding viruses for all of those pathogens. Instead we can find nanoparticles that work effectively on those pathogens and modify the virus to carry that particular nanoparticle to the targeted microorganism. Creating a synergistic effect against the pathogen.</p><p>These nanoparticles work in various ways to fight those pathogens. A simple method is by imagining nanoparticles as tiny spiky balls that puncture bacterial walls like popping a balloon. They can also produce chemicals that can harm those bacteria, followed by many more tricks up their sleeves.</p><h3>Did I Find the Cure?</h3><p>Unfortunately, due to time constraints, I couldn’t complete the project, but I did find some significant knowledge about this topic of AMR and the techniques involved in my journey to achieve my project. Science is a lengthy process and it takes years and many trials and errors to achieve what we want therefore, funding in the scientific field is really essential and also more brilliant curious minds are required. Plus, due to strict regulations that keep scientific research ethical, there is always a delay.</p><p>Science is ever-changing and scientists are constantly unraveling new secrets through their brilliant research, this is the main reason why scholars publish their work, and also for future scientist so they can pick up previous research and make it more efficient.</p><p>So, I guess it’s safe to say that you know why antibiotics are not popcorn for us to snack on every time we have a fever or when we’re feeling under the weather. Next time consult your GP before using them.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5493a5156951" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>